>>NXXQE<<HUGE DD READ HERE>>>O/S SHARES ARE 254 MILLION WITH INSIDERS HOLDING 63 MILLION LEAVING 190 MILLION O/S >> INSIDERS HAVE ONLY SOLD BACK 567,000 IN LAST 12 MONTHS>>> 52 WEEK HIGH .02 >>2 YEAR HIGH .06 >>>>>5 YEAR HIGH OVER $2.00
BETWEEN AUGUST 2011 AND NOVEMBER 2011 NXXQE HAS GENERATED OVER $2 MILLION DOLLARS IN REVENUES WITH HUGE PROFITS AS PER 8-KS!
Nutrition 21 holds over 70 issued and pending patents associated with the essential minerals, other nutrients, and nutrient combinations. Our patent portfolio also includes a number of pharmaceutical drug product technologies covering combinations of nutrients and prescription drugs. These combination products provide the therapeutic benefits of the prescription drug along with the added nutritional support desired by consumers. Some combinations have been clinically shown to provide enhanced efficacy and/or safety compared to the prescription drug without the added nutrient. Our plan is to work with partners and utilize abbreviated regulatory and clinical programs available for these types of combinations to more rapidly obtain FDA approval to bring these products to market. Nutrition 21 technologies provide a platform for out-licensing opportunities to pharmaceutical companies desiring a novel line of drug products or to obtain years of extended patent protection on their current drug portfolio. Drug-nutrient combination drugs in development include treatments for diabetes, , and HIV.
Nutrition 21's Assets Acquired by an Investment Group led by Messrs. Phillip and Michael Satow
11/28/2011
The assets of Nutrition 21 have been acquired by an investment group led by Phillip and Michael Satow. The Company will continue to operate as Nutrition 21.
Michael Satow will serve as President and Chief Executive Officer and Phillip Satow as Chairman of the Board. Phillip and Michael together have almost 50 years of healthcare experience. Most recently, they founded and built JDS Pharmaceuticals, LLC (“JDS”), a specialty pharmaceutical company focused on the psychiatric and women’s health markets. JDS was sold in 2007 to Noven for $125 million.
Prior to JDS, Phillip was Executive Vice President of Forest Laboratories, Inc. and President of Forest Pharmaceuticals as well as a member of the Forest board of directors. Phillip also served in senior positions at Pfizer and Carter Wallace. He has served on the boards of directors of public companies, including Forest Laboratories, Inc. , Crucell Inc., Eyetech, Inc., and Noven. Prior to JDS, Michael founded and/or served as CEO of several venture backed companies as well as practicing as an attorney for five years. Michael currently sits on several private companies and non-profit boards.
Michael Satow commented, “We are very excited about the acquisition of Nutrition 21’s assets. As CEO, I am committing the Company to continuing the highest standards of quality and customer service. We intend to invest in and grow this business as well expand the Company’s range of offerings.”
Phillip Satow stated that, “The nutraceutical and functional food sectors are undergoing significant regulatory and market change. Our knowledge of the healthcare space, combined with the deep experience of Nutrition 21’s personnel will position us well for growth going forward.”
HERE IS WHERE IT IS GREAT>>>>>>BUSINESS AS USUAL....JUST IN SEPTEMBER AND OCTOBER WE GENERATED $1.4 MILLION IN REVENUES AND $1 MILLION IN PROFITS WHILE MAINTAINING $1 MILLION DOLLARS IN ACCOUNTS RECIEVABLE....ABSOLUTELY HUGE!!!!
L2 IS ABSOLUTELY PRIMED FOR A MAJOR EXPLOSION AND BASED ON 4 GREAT DAYS OF TRADING IMO WE CAN EXPECT A HUGE RUNNER HERE....INTEREST IS GROWING EVERYDAY, THE NEXT FEW DAYS ARE GOING TO BE FUN!
PENNIES ARE COMING VERY SOON!
CHARTS SHOW .008 BREAK COMING THEN .0159,,RESISTANCE IS VERY WEEK AT .0033 THEN .0056 BLUE SKIES ARE THE LIMIT!
>>NXXQE<<HUGE DD READ HERE>>>O/S SHARES ARE 254 MILLION WITH INSIDERS HOLDING 63 MILLION LEAVING 190 MILLION O/S >> INSIDERS HAVE ONLY SOLD BACK 567,000 IN LAST 12 MONTHS>>> 52 WEEK HIGH .02 >>2 YEAR HIGH .06 >>>>>5 YEAR HIGH OVER $2.00
BETWEEN AUGUST 2011 AND NOVEMBER 2011 NXXQE HAS GENERATED OVER $2 MILLION DOLLARS IN REVENUES WITH HUGE PROFITS AS PER 8-KS!
Nutrition 21 holds over 70 issued and pending patents associated with the essential minerals, other nutrients, and nutrient combinations. Our patent portfolio also includes a number of pharmaceutical drug product technologies covering combinations of nutrients and prescription drugs. These combination products provide the therapeutic benefits of the prescription drug along with the added nutritional support desired by consumers. Some combinations have been clinically shown to provide enhanced efficacy and/or safety compared to the prescription drug without the added nutrient. Our plan is to work with partners and utilize abbreviated regulatory and clinical programs available for these types of combinations to more rapidly obtain FDA approval to bring these products to market. Nutrition 21 technologies provide a platform for out-licensing opportunities to pharmaceutical companies desiring a novel line of drug products or to obtain years of extended patent protection on their current drug portfolio. Drug-nutrient combination drugs in development include treatments for diabetes, , and HIV.
Nutrition 21's Assets Acquired by an Investment Group led by Messrs. Phillip and Michael Satow
11/28/2011
The assets of Nutrition 21 have been acquired by an investment group led by Phillip and Michael Satow. The Company will continue to operate as Nutrition 21.
Michael Satow will serve as President and Chief Executive Officer and Phillip Satow as Chairman of the Board. Phillip and Michael together have almost 50 years of healthcare experience. Most recently, they founded and built JDS Pharmaceuticals, LLC (“JDS”), a specialty pharmaceutical company focused on the psychiatric and women’s health markets. JDS was sold in 2007 to Noven for $125 million.
Prior to JDS, Phillip was Executive Vice President of Forest Laboratories, Inc. and President of Forest Pharmaceuticals as well as a member of the Forest board of directors. Phillip also served in senior positions at Pfizer and Carter Wallace. He has served on the boards of directors of public companies, including Forest Laboratories, Inc. , Crucell Inc., Eyetech, Inc., and Noven. Prior to JDS, Michael founded and/or served as CEO of several venture backed companies as well as practicing as an attorney for five years. Michael currently sits on several private companies and non-profit boards.
Michael Satow commented, “We are very excited about the acquisition of Nutrition 21’s assets. As CEO, I am committing the Company to continuing the highest standards of quality and customer service. We intend to invest in and grow this business as well expand the Company’s range of offerings.”
Phillip Satow stated that, “The nutraceutical and functional food sectors are undergoing significant regulatory and market change. Our knowledge of the healthcare space, combined with the deep experience of Nutrition 21’s personnel will position us well for growth going forward.”
HERE IS WHERE IT IS GREAT>>>>>>BUSINESS AS USUAL....JUST IN SEPTEMBER AND OCTOBER WE GENERATED $1.4 MILLION IN REVENUES AND $1 MILLION IN PROFITS WHILE MAINTAINING $1 MILLION DOLLARS IN ACCOUNTS RECIEVABLE....ABSOLUTELY HUGE!!!!
L2 IS ABSOLUTELY PRIMED FOR A MAJOR EXPLOSION AND BASED ON 4 GREAT DAYS OF TRADING IMO WE CAN EXPECT A HUGE RUNNER HERE....INTEREST IS GROWING EVERYDAY, THE NEXT FEW DAYS ARE GOING TO BE FUN!
PENNIES ARE COMING VERY SOON!
CHARTS SHOW .008 BREAK COMING THEN .0159,,RESISTANCE IS VERY WEEK AT .0033 THEN .0056 BLUE SKIES ARE THE LIMIT!
News 
Market Data 
Discover 
